Last updated: February 23, 2026
What is NDC 72888-0060?
NDC 72888-0060 identifies Ocrevus (Ocrelizumab), a monoclonal antibody developed by Roche used for multiple sclerosis (MS), including relapsing-remitting MS and primary progressive MS. Approved by the FDA in 2017, it has become a key therapy in the disease-modifying drug (DMD) market for MS.
Market Size and Growth
Market Overview
The global MS therapeutics market was valued at USD 22.7 billion in 2021 and is expected to reach USD 31.1 billion by 2026, growing at a CAGR of approximately 6.3%. Ocrevus accounts for a significant portion of this market, especially in the US and Europe.
Patient Population
- Estimated prevalence in the US: 1 million MS patients.
- Eligible for Ocrevus treatment: active relapsing or primary progressive MS.
- Market penetration in MS diagnosed patients: approximately 50-60%.
Competitive Landscape
Major competitors include:
- Biogen’s Tecfidera (dimethyl fumarate)
- Novartis’s Gilenya (fingolimod)
- Eli Lilly’s Tofacitinib (emerging)
- Sanofi’s Aubagio (teriflunomide)
Ocrevus leads in efficacy for primary progressive MS and has a favorable dosing schedule (every six months), providing a competitive advantage.
Pricing and Revenue Trends
Current Price Structure
- In the US, the Wholesale Acquisition Cost (WAC) for Ocrevus per 300 mg vial is approximately USD 3,800.
- Typical dosing schedule: 600 mg (two 300 mg vials) every six months for a standard patient.
- Annual drug cost per patient: USD 7,600 (excluding administration and other costs).
Market Revenue Estimates
| Year |
Estimated US Revenue (USD billions) |
Notes |
| 2021 |
1.1 |
Market penetration at ~30% of eligible patients. |
| 2022 |
1.3 |
Increased adoption; expanded indication for primary progressive MS. |
| 2023 |
1.5 |
Price adjustments and increased patient uptake. |
| 2024 |
1.7 |
Anticipated stabilization with competitive pressures. |
Global Prices
- Europe prices are similar but vary by country; typically EUR 3,700–4,200 per vial.
- Emerging markets: significantly lower, USD 2,000–3,000 per vial, with reduced access.
Price Trends
- No significant price decrease expected in the short term due to patent protection.
- Biosimilar entry unlikely before 2027 due to patent hurdles and regulatory pathways.
- Price inflation averaged approximately 2-3% annually in the US in recent years.
Patent and Regulatory Considerations
- U.S. patent protections extend until 2027, with potential extensions or litigation outcomes influencing market exclusivity.
- Biosimilars are anticipated to enter the market post-2027, exerting downward pressure on prices.
Future Market and Price Projections
Factors Influencing Future Prices
- Patent litigation outcomes: Could delay biosimilar entry.
- Market penetration: Increased diagnosis and diagnosis accuracy.
- Pricing policies: Government-led price negotiations, especially in Europe and Canada.
- Biosimilar development: Entry expected after 2027, potentially reducing prices by 20–40%.
Projected Price Trends (Next 5 Years)
| Year |
Estimated WAC per 300 mg vial |
Comments |
| 2024 |
USD 3,900–4,000 |
Stabilization with minor inflation. |
| 2025 |
USD 3,950–4,050 |
Slight increase due to inflation and demand. |
| 2026 |
USD 4,000–4,100 |
Approaching patent expiry, biosimilar entry anticipated. |
| 2027 |
USD 3,500–3,700 |
Biosimilar competition likely reduces prices. |
Impact of Biosimilars
- Biosimilar candidates are under development targeting Ocrevus.
- Pricing could decline by up to 50% post-2027, with market share sharing expected among biosimilars and originator.
Summary Analysis
| Aspect |
Data/Estimate |
| Market size (2023) |
USD 1.5 billion US sales, global USD 2.5 billion. |
| Price per vial |
USD 3,800 (current), expected USD 3,500–3,700 post-2027. |
| Revenue growth |
8–10% CAGR until patent expiration, then decline as biosimilars penetrate. |
| Key factors |
Patent protection duration, biosimilar development, regulatory pathways, market penetration rates. |
Key Takeaways
- The US MS drug market, driven by Ocrevus, is expected to grow at a 6-8% annual rate until biosimilar entry.
- Current pricing remains stable, with modest increases to offset inflation.
- Biosimilar competition expected after 2027 will significantly impact pricing and market share.
- Price projections suggest a decline post-patent expiry, with potential reductions up to 50% due to biosimilar competition.
- Market expansion depends on diagnostic rates, treatment guidelines, and regulatory policies influencing drug penetration.
FAQs
1. What is the main driver of Ocrevus pricing stability?
Patent rights until 2027 and limited biosimilar competition limit downward pressure on prices.
2. How will biosimilars impact market prices?
Biosimilars are expected to reduce market prices by 20–50% once approved and adopted, typically a few years post-2027.
3. What regions are most lucrative for Ocrevus?
The US remains the largest market due to high prevalence and reimbursement strategies. Europe follows closely.
4. Are there upcoming regulatory changes affecting pricing?
Price negotiations are increasing in countries like Canada and European nations but less so in the US where lack of government negotiation caps pricing.
5. Will new therapies challenge Ocrevus’s market share significantly?
Emerging therapies with improved efficacy or safety profiles could gain market share, but Ocrevus’s dosing schedule and indication breadth provide advantages.
References
[1] Statista. (2022). Multiple sclerosis market size worldwide. https://www.statista.com/
[2] FDA. (2017). Ocrevus (Ocrelizumab) Prescribing Information.
[3] IQVIA. (2023). MS Therapeutics Market Analysis.
[4] Biosimilar Development News. (2023). Biosimilar pipeline for MS treatments.
[5] European Medicines Agency. (2022). Ocrelizumab marketing authorization details.
